Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 4, 2011, Pages 264-268

  Pelet, Anne ^a   Favrat, Bernard ^a   Cavassini, Matthias ^a   Eap, Chin B ^a,b   Besson, Jacques ^c   Monnat, Martine ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Methadone; Pharmacokinetic; Plasma trough level and withdrawal symptoms

Indexed keywords

ANTIRETROVIRUS AGENT; BOSENTAN; EFAVIRENZ; METHADONE; NEVIRAPINE;

ANXIETY DISORDER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL TRANSIT; HEALTH CARE PERSONNEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPIATE WITHDRAWAL SYMPTOM; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SYMPTOM; VOMITING; WITHDRAWAL SYNDROME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; METHADONE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 79960381848     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.591465     Document Type: Article

References (28)

1. Mitty JA, Macalino GE, Bazerman LB, Loewenthal HG, Hogan JW, MacLeod CJ, Flanigan TP. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr 2005; 39(5):545-550. (Pubitemid 41098468)
2. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: Evidence from the MANIF2000 cohort study. Addiction 2008: 103(11) 1828-36
3. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42(11):1628-1635.
4. Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, Caliendo AM, Flanigan TP. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 2007; 21(11):1473-1477. (Pubitemid 46988008)
5. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: The role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84(2):188-194. (Pubitemid 44119095)
6. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Phar-macokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41(5):563-572.
7. Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med 2000; 1(Suppl. 1):15-17.
8. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. Pharmacokinetic interactions of nevirap-ine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001; 33(9):1595-1597. (Pubitemid 34246157)
9. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, Back DJ. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51(3):213-217. (Pubitemid 32391497)
10. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 2000; 14(9):1291-1292. (Pubitemid 30420682)
11. Tossonian HK, Raffa JD, Grebely J, Trotter B, Viljoen M, Mead A, Khara M, McLean M, Duncan F, Fraser C, DeVlaming S, Conway B. Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. J Acquir Immune Defic Syndr 2007; 45(3):324-327. (Pubitemid 47012380)
12. McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict 2002; 11(4):271-278. (Pubitemid 35332504)
13. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13(8): 957-962. (Pubitemid 29240191)
14. Arroyo E, Valenzuela B, Portilla J, Climent-Grana E, Perez-Ruixo JJ, Merino E. Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Eur J Clin Pharmacol 2007; 63(7): 669-675. (Pubitemid 46911339)
15. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert. AIDS 1999; 13(8): 1004-1005. (Pubitemid 29240204)
16. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000; 34(3):405-407. (Pubitemid 30133611)
17. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41(14):1153-1193. (Pubitemid 35398691)
18. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80(6):668-681. (Pubitemid 44920225)
19. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78(6):593-604. (Pubitemid 41773635)
20. Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Deglon J. Plasma concentrations of the enan-tiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61(1): 47-54.
21. Adinoff B. Divided doses for methadone maintenance. Am J Psychiatry 2008; 165(3):303-305. (Pubitemid 351704481)
22. Barlett JG, Lane HC and al panel on antiretroviral guidelines for adults and adolescents. In Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Vol. 3. Washington, DC: Department of Health and Human Services, 2008; 1-139.
23. Calvo R, Lukas JC, Rodriguez M, Carlos MA, Suarez E. Phar-macokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. Br J Clin Pharmacol 2002; 53(2):212-214. (Pubitemid 34264280)
24. Kapadia F, Vlahov D, Wu Y, Cohen MH, Greenblatt RM, Howard AA, Cook JA, Goparaju L, Golub E, Richardson J, Wilson TE. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seroposi-tive women. Am J Drug Alcohol Abuse 2008; 34(2):161-170. (Pubitemid 351302169)
25. Santos CQ, Adeyemi O, Tenorio AR. Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital. AIDS Care 2006; 18(7):808-811. (Pubitemid 44395528)
26. McCance-Katz EF. Treatment of opioid dependence and coin-fection with HIV and hepatitis C virus in opioid-dependent patients: The importance of drug interactions between opi-oids and antiretroviral agents. Clin Infect Dis 2005; 41(Suppl. 1):S89-S95. (Pubitemid 40863732)
27. McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 2010: 19(1): 30-37.
28. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A cross-sectional study. Addiction 2007; 102(2):289-300. (Pubitemid 46096291)